Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,854,613
  • Shares Outstanding, K 144,487
  • Annual Sales, $ 223,810 K
  • Annual Income, $ -245,190 K
  • 60-Month Beta 2.81
  • Price/Sales 26.13
  • Price/Cash Flow N/A
  • Price/Book 15.04

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.41
  • Number of Estimates 6
  • High Estimate -0.38
  • Low Estimate -0.44
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +18.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.35 +14.63%
on 10/02/19
44.85 -9.65%
on 09/16/19
-0.87 (-2.10%)
since 09/11/19
3-Month
21.56 +87.94%
on 07/23/19
44.85 -9.65%
on 09/16/19
+13.27 (+48.70%)
since 07/11/19
52-Week
14.01 +189.22%
on 12/24/18
44.85 -9.65%
on 09/16/19
+19.53 (+93.04%)
since 10/11/18

Most Recent Stories

More News
Shares of ACAD Up 0.6% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Acadia Pharmaceu (NASDAQ:ACAD) on September 9th, 2019 at $40.30. In approximately 1 month, Acadia Pharmaceu has returned 0.62% as of today's recent price of $40.55....

ACAD : 40.52 (+0.10%)
SmarTrend Watching for Potential Pullback in Shares of Acadia Pharmaceu After 1.55% Gain

Acadia Pharmaceu (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $39.11 to a high of $40.37. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high...

ACAD : 40.52 (+0.10%)
Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates

Key highlights of the past week include label expansion of drugs, licensing deals and more.

PFE : 36.11 (unch)
VSTM : 1.09 (-2.68%)
ACAD : 40.52 (+0.10%)
GILD : 63.93 (-0.09%)
IONS : 62.74 (+1.03%)
AKCA : 19.75 (+0.46%)
ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that based on secondary analyses from its Phase 2 CLARITY study, adjunctive pimavanserin showed the potential to improve symptoms of sexual dysfunction...

ACAD : 40.52 (+0.10%)
ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimer's Disease (CTAD) 2019 Meeting

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the presentation of the results from the Phase 3 HARMONY study of pimavanserin in dementia-related psychosis has been accepted for a late-breaking...

ACAD : 40.52 (+0.10%)
SmarTrend Watching for Potential Rebound in Shares of Acadia Pharmaceu After 1.93% Loss

Acadia Pharmaceu (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $35.89 to a high of $38.41. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of...

ACAD : 40.52 (+0.10%)
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?

Style Box ETF report for FNY

FNY : 45.26 (+1.50%)
IWP : 141.94 (+1.39%)
ACAD : 40.52 (+0.10%)
FCN : 110.72 (+0.89%)
ROKU : 121.55 (-0.04%)
IJK : 222.40 (+1.49%)
ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system...

ACAD : 40.52 (+0.10%)
ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder

--- Phase 3 CLARITY program initiated in April 2019

ACAD : 40.52 (+0.10%)
Overstock.com and Akcea slip while Acadia and Insulet gain

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday.

PODD : 151.00 (-1.56%)
AKCA : 19.75 (+0.46%)
GM : 35.57 (+2.63%)
ACAD : 40.52 (+0.10%)
MNK : 2.30 (+1.32%)
OSTK : 10.60 (-0.66%)
HYMTF : 29.8900 (+6.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade ACAD with:

Business Summary

Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104...

See More

Key Turning Points

2nd Resistance Point 41.20
1st Resistance Point 40.86
Last Price 40.52
1st Support Level 40.15
2nd Support Level 39.78

See More

52-Week High 44.85
Last Price 40.52
Fibonacci 61.8% 33.07
Fibonacci 50% 29.43
Fibonacci 38.2% 25.79
52-Week Low 14.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar